Less than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy can access them, caution the World Health Organization as it issues its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
According to projections, more than two billion will be living with obesity by 2030 unless action is taken.
"The new guidelines recognises that obesity is a chronic disease that can be managed with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major barriers to widespread availability to the injections that can help people shift significant weight, says the organization.
Weight-Loss Drug Shortage
Even under the present most optimistic scenario, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of those who need them, per the WHO.
The advice encourages governments and firms to increase availability, via measures like voluntary licensing.
A patent on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Jabs Operate
These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and boost satiety so users consume fewer calories.
Patients commonly see weight reduction after several weeks of beginning the regular doses.
Evidence suggests people may regain a significant portion after a year of halting the drug, because their normal appetite resume.
Being overweight or obese elevates your risk for experiencing diseases, like diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight concerns people in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
